Patents by Inventor Isaac Ciechanover

Isaac Ciechanover has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Administration of an anti-activin-a compound to a subject
    Patent number: 12383572
    Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.
    Type: Grant
    Filed: December 22, 2022
    Date of Patent: August 12, 2025
    Assignees: AMGEN INC., Atara Biotherapeutics, Inc.
    Inventors: Huiquan Han, Christopher Michael Haqq, Isaac Ciechanover, Xiaolan Zhou, John Zhao-Nian Lu
  • Administration of an anti-activin-A compound to a subject
    Patent number: 11541070
    Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: January 3, 2023
    Assignee: Atara Biotherapeutics, Inc.
    Inventors: Huiquan Han, Christopher Michael Haqq, Isaac Ciechanover, Xiaolan Zhou, John Zhao-Nian Lu
  • Myostatin Antagonism in Human Subjects
    Publication number: 20160038588
    Abstract: Disclosed are methods of treating or modulating cachexia and/or increasing lean body mass and/or increasing lower extremity muscle size in a prostate cancer patient comprising administering a therapeutically effective amount of a myostatin antagonist. Further disclosed is the peptibody sequence of the myostatin antagonist, and the formulation of the peptibody.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 11, 2016
    Inventors: Ian Desmond Padhi, Huiquan Han, Christopher Michael Haqq, Isaac Ciechanover
  • ADMINISTRATION OF AN ANTI-ACTIVIN-A COMPOUND TO A SUBJECT
    Publication number: 20150359850
    Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.
    Type: Application
    Filed: February 3, 2014
    Publication date: December 17, 2015
    Applicants: SANTA MARIA BIOTHERAPEUTICS, INC., AMGEN INC.
    Inventors: Huiquan Han, Christopher Michael Haqq, Isaac Ciechanover, Xiaolan Zhou, John Zhao-Nian Lu
  • Administration of an Anti-Activin-A Compound to a Subject
    Publication number: 20140220033
    Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment by evaluating the subject's expression levels of specific biomarkers or angiogenic factors.
    Type: Application
    Filed: February 3, 2014
    Publication date: August 7, 2014
    Applicants: Santa Maria Biotherapeutics, Inc., Amgen Inc.
    Inventors: Huiquan Han, Isaac Ciechanover, Christopher Michael Haqq, Xiaolan Zhou, John Zhao-Nian Lu